

**IN THE CLAIMS:**

1-32. (Previously Cancelled)

33. (Previously Cancelled)

34. (Previously Cancelled)

35. (Original) The method of claim 33, wherein the compound comprises a composition selected from the group consisting of a jatrophane, a jatrophane derivative and a pharmaceutically acceptable salt of a jatrophane or a jatrophane derivative.

36. (Original) The method of claim 35, wherein the compound comprises a composition comprising a jatrophane ring conformation.

37. (Original) The method of claim 36, wherein the jatrophane ring containing composition is present in two diastereomeric conformations.

38. (Original) The method of claim 36, wherein the jatrophane ring containing composition is present in one diastereomeric conformation.

39. (Original) The method of claim 38, wherein the diastereomeric conformation is a conformation II.

40. (Original) The method of claim 36, wherein the composition comprising a jatrophone ring conformation comprises a nicotinate moiety.

41. (Original) The method of claim 36, wherein the composition comprising a jatrophone ring conformation comprises a benzoate moiety.

42. (Original) The method of claim 36, wherein the composition comprising a jatrophone ring conformation comprises a iso-butyrate moiety.

43. (Original) The method of claim 33, wherein the jatrophone derivative comprises an ester derivative.

44. (Original) The method of claim 33, wherein the jatrophone derivative comprises an acetylated derivative.

45. (Original) The method of claim 36, wherein the jatrophone derivative comprises a substitution in the jatrophone ring carbon 1 position of a moiety selected from the group consisting of a -H and a -OAc.

46. (Original) The method of claim 36, wherein the jatrophone derivative comprises a substitution in the jatrophone ring carbon 2 position of a moiety selected from the group consisting of a -H, a -OAc and a CH<sub>3</sub>.

47. (Original) The method of claim 36, wherein the jatrophone derivative comprises a substitution in the jatrophone ring carbon 3 position of a moiety selected from the group consisting of a -OH, a -OAc, a -OiBu ( $\text{O}(\text{CH}_3)_2\text{CHCO}$ ), a -OCinn, a -OBz, a -OBzOCH<sub>2</sub>CO, and a -PhCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>.

48. (Original) The method of claim 36, wherein the jatrophone derivative comprises a substitution in the jatrophone ring carbon 4 position of an -H.

49. (Original) The method of claim 36, wherein the jatrophone derivative comprises a substitution in the jatrophone ring carbon 5 position of a moiety selected from the group consisting of a -OAc, a -OiBu ( $\text{O}(\text{CH}_3)_2\text{CHCO}$ ), -OMeBu ( $\text{OCH}_3\text{CH}_2\text{CH}(\text{CH}_3)\text{CO}$ ) and a -OAcAc.

50. (Original) The method of claim 36, wherein the jatrophone derivative comprises a substitution in the jatrophone ring carbon 6 position of a moiety comprising an exocyclic double bond.

51. (Original) The method of claim 36, wherein the jatrophone derivative comprises a substitution in the jatrophone ring carbon 7 position of an -H<sub>2</sub>, a -OAc, a -OiBu ( $\text{O}(\text{CH}_3)_2\text{CHCO}$ ), a -OmeBu ( $\text{OCH}_3\text{CH}_2\text{CH}(\text{CH}_3)\text{CO}$ ), a -OPr, a -OCOiPr and a -OCOEt.

52. (Original) The method of claim 36, wherein the jatrophone derivative comprises a

substitution in the jatrophane ring carbon 8 position of an  $-H_2$ , a  $-OH$ , a  $-OAc$ , a  $-OiBu$  ( $O(CH_3)_2CHCO$ ), a  $-OmeBu$  ( $OCH_3CH_2CH(CH_3)CO$ ), a  $-OBz$  and a  $-OAng$ .

53. (Original) The method of claim 36, wherein the jatrophane derivative comprises a substitution in the jatrophane ring carbon 9 position of an  $-OH$ , a  $-OAc$  ( $-OCH_3CO$ ), a  $-OCinn$  ( $OPhCHCHCO$ ), a  $-ONic$  ( $C_5H_4NCO_2$ ) and an  $=O$ .

54. (Original) The method of claim 36, wherein the jatrophane derivative comprises a substitution in the jatrophane ring carbon 10 position of a  $-(CH_3)_2$ .

55. (Original) The method of claim 36, wherein the jatrophane derivative comprises a substitution in the jatrophane ring carbon 11 and carbon 12 positions comprising a double bond between carbon 10 and carbon 11.

56. (Original) The method of claim 36, wherein the jatrophane derivative comprises a substitution in the jatrophane ring carbon 13 position of a  $-(CH_3)$ .

57. (Original) The method of claim 36, wherein the jatrophane derivative comprises a substitution in the jatrophane ring carbon 14 position of an  $-H$ , an  $-OH$ , a  $-OAc$  ( $OCH_3CO$ ) and an  $=O$ .

58. (Original) The method of claim 36, wherein the jatrophane derivative comprises a substitution in the jatrophane ring carbon 15 position of an  $-OH$  and a  $-OAc$  ( $OCH_3CO$ ).

59. (Original) The method of claim 35, wherein the composition comprises a 2,3,5,7,15-pentaacetoxy-9-nicotinoyloxy-14-oxojatropha-6(17), 11*E*-diene (jatrophane 1) or a pharmaceutically acceptable salt.
60. (Original) The method of claim 35, wherein the composition comprises a 2,5,7,8,9,14-hexaacetoxy-3-benzoyloxy-15-hydroxy-jatropha-6(17), 11*E*-diene (jatrophane 2) or a pharmaceutically acceptable salt.
61. (Original) The method of claim 35, wherein the compound comprises a 2,5,14-triacetoxy-3-benzoyloxy-8, 15-dihydroxy-7-isobutyroyloxy-9-nicotinoyloxyjatropha-6(17), 11*E*-diene (jatrophane 3) or a pharmaceutically acceptable salt of these.
62. (Original) The method of claim 35, wherein the compound comprises a 2,5,9,14-tetraacetoxy-3-benzoyloxy-8, 15-dihydroxy-7-isobutyroyloxyjatropha-6(17), 11*E*-diene (jatrophane 4) or a pharmaceutically acceptable salt of these.
63. (Original) The method of claim 35, wherein the compound comprises a 2,5,7,14-tetraacetoxy-3-benzoyloxy-8, 15-dihydroxy-9-nicotinoyloxyjatropha-6(17), 11*E*-diene (jatrophane 5) or a pharmaceutically acceptable salt of these.
64. (Original) The method of claim 35, wherein the compound comprises a 2,5,7,9,14-pentaacetoxy-3-benzoyloxy-8, 15-dihydroxyjatropha-6(17), 11*E*-diene (jatrophane 6) or a

pharmaceutically acceptable salt of these.

65. (Original) The method of claim 33, wherein the compound comprises a composition selected from the group consisting of a pepluane, a pepluane derivative and a pharmaceutically acceptable salt of a pepluane or a pepluane derivative.

66. (Original) The method of claim 65, wherein the pepluane derivative comprises an ester derivative.

67. (Original) The method of claim 65, wherein the pepluane derivative comprises an acetylated derivative.

68. (Original) The method of claim 65, wherein the pepluane derivative comprises a substitution in a position in a pepluane skeleton selected from the group consisting of

an -H<sub>2</sub> or an -OAc (-OCH<sub>3</sub>CO) at a carbon 1 position;

a -CH<sub>3</sub> and an -H at a carbon 2 position;

an -OBz at a carbon 3 position; an -H at a carbon 4 position;

an -OAc (-OCH<sub>3</sub>CO) at a carbon 5 position;

a -CH<sub>3</sub> or an -CH<sub>2</sub>OAc at a carbon 6 position;

an -H<sub>2</sub> at a carbon 7 position;

an -OAc (-OCH<sub>3</sub>CO) or a double bond to C12 at a carbon 8 position;

an -OAc (-OCH<sub>3</sub>CO) or a double bond to C18 at a carbon 9 position;

a -CH<sub>3</sub> and an -OAc (-OCH<sub>3</sub>CO), a -CH<sub>3</sub>, or a double bond to C11 at a carbon 10

position;

an -H<sub>2</sub> or a double bond to C10 at a carbon 11 position;

an -H or a double bond to C8 at a carbon 12 position;

a -CH<sub>3</sub> at a carbon 13 position;

an -OAc (-OCH<sub>3</sub>CO) at a carbon 14 position; an -OH at a carbon 15 position; and

an -H or an -H<sub>2</sub> at a carbon 18 position.

69. (Original) The method of claim 65, wherein the pepluane comprises a composition selected from the group consisting of a 5,8,9,10,14-pentaacetoxy-3-benzoyloxy-15-hydroxypepluane, a derivative of a 5,8,9,10,14-pentaacetoxy-3-benzoyloxy-15-hydroxypepluane and a pharmaceutically acceptable salt of a 5,8,9,10,14-pentaacetoxy-3-benzoyloxy-15-hydroxypepluane.

70. (Original) The method of claim 33, wherein the compound comprises a composition selected from the group consisting of a paraliane, a paraliane derivative and a pharmaceutically acceptable salt of a paraliane or a paraliane derivative.

71. (Original) The method of claim 70, wherein the paraliane derivative comprises an ester derivative.

72. (Original) The method of claim 70, wherein the paraliane derivative comprises an acetylated derivative.

73. (Original) The method of claim 70, wherein the paraliene derivative comprises a substitution in a position in a paraliene skeleton selected from the group consisting of

- an -H, an -H<sub>2</sub> or an -OAc (-OCH<sub>3</sub>CO) at a carbon 1 position;
- a -CH<sub>3</sub> and an -H or a -CH<sub>3</sub> and an -OAc (-OCH<sub>3</sub>CO) at a carbon 2 position;
- an -OBz at a carbon 3 position;
- an -H at a carbon 4 position; an -OAc (-OCH<sub>3</sub>CO) at a carbon 5 position;
- a -CH<sub>3</sub> or a -CH<sub>2</sub>OAc at a carbon 6 position;
- an -H<sub>2</sub> at a carbon 7 position;
- an -H or an -OAc (-OCH<sub>3</sub>CO) at a carbon 8 position;
- an = O at a carbon 9 position;
- a -(CH<sub>3</sub>)<sub>2</sub> at a carbon 10 position;
- an -H<sub>2</sub> at a carbon 11 position;
- an -H at a carbon 12 position;
- a -CH<sub>3</sub> at a carbon 13 position;
- an -OAc (-OCH<sub>3</sub>CO) at a carbon 14 position; and,
- an -OH at a carbon 15 position.

74. (Previously Cancelled)

75. (Previously Cancelled)

76. (Previously Cancelled)

77. (Previously Cancelled)



78. (Previously Cancelled)

79. (Previously Cancelled)

80. (Previously Cancelled)

81. (Previously Cancelled)

82. (Previously Cancelled)

83. (Currently Cancelled)

84. (Previously Cancelled)

85. (Previously Cancelled)

86. (Previously Cancelled)

87. (Previously Cancelled)

88. (Previously Cancelled)

89. (Previously Cancelled)

90. (Original) A method of treating a subject with a cancer, the method comprising administering to the subject an effective amount of at least two compounds,

wherein the two compounds are derived from an extract from the sap of a species of *Euphorbia*, wherein the compounds

(a) are extractable from the *Eupliorbia* sap in the presence of about 95% v/w

ethanol,

(b) have cell inhibiting or retarding activity which is neither destroyed by acetone nor by heating at about 95°C for about 15 minutes, and

(c) are capable of inhibiting the growth of at least one cell line selected from the group consisting of MM96L, MM229, MM220, MM537, MM2058, HeLa, B16, LIM1215, A549, MCF7, MCC16 and Colo16.

91. (Original) The method of claim 90, wherein the compounds are selected from the group consisting of a jatrophone, a jatrophone derivative, a pharmaceutically acceptable salt of a jatrophone, a pepluane, a pepluane derivative, a pharmaceutically acceptable salt of a pepluane, a paraliane, a paraliane derivative, a pharmaceutically acceptable salt of a paraliane, an angeloyl-substituted ingenane, an angeboyl-substituted ingenane derivative and a pharmaceutically acceptable salt of an angeboyl-substituted ingenane.

92. (Original) The method of claim 90, wherein the compounds are selected from the group consisting of a 5,8,9,10,14-pentaacetoxy-3-benzoyloxy-15-hydroxy-pepluane (pepluane), a derivative of a 5,8,9,10,14-pentaacetoxy-3-benzoyloxy-15-hydroxy-pepluane, a 2,3,5,7,15-pentaacetoxy-9-nicotinoyloxy-14-oxojatropha-6(17), 11*E*-diene (jatrophone 1), a derivative of a 2,3,5,7,15-pentaacetoxy-9-nicotinoyloxy-14-oxojatropha-6(17), 11*E*-diene, a 2,5,7,8,9,14-hexaacetoxy-3-benzoyloxy-15-hydroxy-jatropha-6(17), 11*E*-diene (jatrophone 2), a derivative of a 2,5,7,8,9,14-hexaacetoxy-3-benzoyloxy-15-hydroxy-jatropha-6(17), 11*E*-diene, a 2,5,14-triacetoxy-3-benzoyloxy-8, 15-dihydroxy-7-isobutyroyloxy-9-nicotinoyloxy-jatropha-6(17), 11*E*-diene (jatrophone 3), a derivative of a 2,5,14-triacetoxy-3-benzoyloxy-8, 15-dihydroxy-7-

isobutyroyloxy-9-nicotinoyloxy-jatropha-6(17), 11*E*-diene, a 2,5,9,14-tetraacetoxy-3-benzoyloxy-8, 15-dihydroxy-7-isobutyroyloxy-jatropha-6(17), 11*E*-diene (jatropane 4), a derivative of a 2,5,9,14-tetraacetoxy-3-benzoyloxy-8, 15-dihydroxy-7-isobutyroyloxy-jatropha-6(17), 11*E*-diene, a 2,5,7,14-tetraacetoxy-3-benzoyloxy-8, 15-dihydroxy-9-nicotinoyloxy-jatropha-6(17), 11*E*-diene (jatropane 5), a derivative of a 2,5,7,14-tetraacetoxy-3-benzoyloxy-8, 15-dihydroxy-9-nicotinoyloxy-jatropha-6(17), 11*E*-diene, a 2,5,7,9,14-pentaacetoxy-3-benzoyloxy-8, 15-dihydroxy-jatropha-6(17), 11*E*-diene (jatropane 6), a derivative of a 2,5,7,9,14-pentaacetoxy-3-benzoyloxy-8, 15-dihydroxy-jatropha-6(17), 11*E*-diene, a 20-O-acetyl-ingenol-3-angelate, a derivative of a 20-O-acetyl-ingenol-3-angelate and pharmaceutically acceptable salt of one or any combination of these compounds.

93. (Original) The method of claim 90, wherein the compounds are provided in the form of a chemical fraction obtained from the sap of a species of *Euphorbia*.

94. (Previously Cancelled)

95. (Previously Cancelled)

96. (Previously Cancelled)

97. (Previously Cancelled)

98. (Previously Cancelled)

99. (Previously Cancelled)

100. (Currently Amended) A method of treating a subject with cancer, the method comprising administering to the subject in need thereof a therapeutically effective amount of at least one isolated compound selected from the group consisting of an angeloyl-substituted ingenane ~~obtainable~~ obtained from the sap of a *Euphorbia species* and an active derivative of an angeloyl-substituted ingenane obtainable from the sap of a *Euphorbia species*, wherein said active derivative exhibits the same anti-cancer activity as said angeloyl-substituted ingenane.

101. (Previously Presented) The method of claim 100, wherein the *Euphorbia species* is *Euphorbia peplus*.

102. (Previously Presented) The method of claim 100, wherein the *Euphorbia species* is *Euphorbia drummondii*.

103. (Previously Presented) The method of claim 100, wherein the *Euphorbia species* is *Euphorbia hirta*.

104. (Previously Presented) The method of Claims 101, wherein the derivative of an angeloyl-substituted ingenane obtained from the sap of *Euphorbia peplus* is an acetylated derivative.

105. (Previously Presented) The method of Claim 102, wherein the derivative of an angeloyl-substituted ingenane obtained from the sap of *Euphorbia drummondii* is an acetylated derivative.

106. (Previously Presented) The method of Claim 103, wherein the derivative of an angeloyl-substituted ingenane obtained from the sap of *Euphorbia hirta* is an acetylated derivative.

107. (Previously Presented) The method of any one of Claims 100 to 103, wherein the at least one compound is selected from the group consisting of a 20-O-acetyl-ingenol-3-angelate and an ester derivative of a 20-O-acetyl-ingenol-3-angelate.

108. (Previously Presented) The method of any one of Claims 100 to 103, wherein the compound comprises a pharmaceutically acceptable salt of the 20-O-acetyl-ingenol-3-angelate and the 20-O-acetyl-ingenol-3-angelate ester derivative.

109. (Previously Presented) The method of any one of Claims 100 to 103, wherein the compound is obtained by the process of extracting said sap with 95% v/v ethanol, discarding a solid fraction and retaining a soluble fraction.

110. (Previously Presented) The method of any one of Claims 100 to 103, wherein the cancer is a solid tumor.

111. (Previously Presented) The method of any one of Claims 100 to 103, wherein the cancer is colon cancer.

112. (Previously Presented) The method of any one of Claims 100 to 103, wherein the cancer is lung cancer.

113. (Previously Presented) The method of any one of Claims 100 to 103, wherein the cancer is prostate cancer.

114. (Previously Presented) The method of any one of Claims 100 to 103, wherein the cancer is cervical cancer.

115. (Previously Presented) The method of any one of Claims 100 to 103, wherein the cancer is breast cancer.